logo
Plus   Neg
Share
Email

Amgen, Adaptive Partner To Find Neutralizing Antibodies For COVID-19

Amgen (AMGN) and Adaptive Biotechnologies (ADPT) announced they will collaborate to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The companies will begin work immediately and finalize financial terms in the coming weeks.

Adaptive Biotechnologies will extend its high throughput platform to screen the genetic diversity of the B cell receptors from individuals that have recovered from COVID-19. This enables the identification of antibodies from survivors of COVID-19 to select those that neutralize SARS-CoV-2.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
Follow RTT